BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10215647)

  • 21. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
    McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
    Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.
    Harirforoosh S; Jamali F
    Can J Physiol Pharmacol; 2005 Jan; 83(1):85-90. PubMed ID: 15759054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
    Dilger K; Herrlinger C; Peters J; Seyberth HW; Schweer H; Klotz U
    J Clin Pharmacol; 2002 Sep; 42(9):985-94. PubMed ID: 12211224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
    Belton OA; Duffy A; Toomey S; Fitzgerald DJ
    Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids.
    Agnoli GC; Borgatti R; Cacciari M; Lenzi P; Marinelli M; Stipo L
    Prostaglandins Leukot Essent Fatty Acids; 2001 Feb; 64(2):95-103. PubMed ID: 11237476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
    Takeeda M; Hayashi Y; Yamato M; Murakami M; Takeuchi K
    J Physiol Pharmacol; 2004 Mar; 55(1 Pt 2):193-205. PubMed ID: 15082878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin.
    Schwartz JI; Musser BJ; Tanaka WK; Taggart WV; Mehta A; Gottesdiener KM; Greenberg HE
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):337-45. PubMed ID: 27137142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.
    Tanigawa T; Watanabe T; Hamaguchi M; Sasaki E; Tominaga K; Fujiwara Y; Oshitani N; Matsumoto T; Higuchi K; Arakawa T
    Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G148-56. PubMed ID: 12958020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
    Brzozowski T; Konturek PC; Konturek SJ; Pajdo R; Schuppan D; Drozdowicz D; Ptak A; Pawlik M; Nakamura T; Hahn EG
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):751-73. PubMed ID: 11192947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
    Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
    Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective cyclooxygenase-2 inhibition by nimesulide in man.
    Cullen L; Kelly L; Connor SO; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
    Khan AA; Brahim JS; Rowan JS; Dionne RA
    Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
    Stichtenoth DO; Marhauer V; Tsikas D; Gutzki FM; Frölich JC
    Kidney Int; 2005 Nov; 68(5):2197-207. PubMed ID: 16221219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury.
    Tsugawa K; Hashizume M; Migou S; Kishihara F; Kawanaka H; Tomikawa M; Sugimachi K
    J Gastroenterol Hepatol; 1999 Jul; 14(7):642-51. PubMed ID: 10440208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD.
    Montuschi P; Macagno F; Parente P; Valente S; Lauriola L; Ciappi G; Kharitonov SA; Barnes PJ; Ciabattoni G
    Thorax; 2005 Oct; 60(10):827-33. PubMed ID: 16192367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
    Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
    Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
    Weber AA; Heim HK; Schumacher M; Schrör K; Hohlfeld T
    Platelets; 2007 Aug; 18(5):379-85. PubMed ID: 17654308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
    Wang W; Zolty E; Falk S; Summer S; Stearman R; Geraci M; Schrier R
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1131-6. PubMed ID: 17652370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of eicosanoid mediation of the renal functional effects of hyperchloremia.
    Askari B; Bell-Quilley CP; Fulton D; Quilley J; McGiff JC
    J Pharmacol Exp Ther; 1997 Jul; 282(1):101-7. PubMed ID: 9223545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.